Trial Profile
Evaluation for efficacy and toxicity of Nivolumab monotherapy for advanced non-small cell lung cancer after first-line treatment failure based on second-generation sequencing and liquid chip platform
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Adverse reactions; Biomarker; Pharmacodynamics; Pharmacogenomic; Therapeutic Use
- 04 Oct 2018 New trial record